REGENERON PHARMACEUTICALS INC. - COMMON STOCK

Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

18 Dec 2023 15:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

15 Dec 2023 08:46:55 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

13 Dec 2023 08:45:17 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

12 Dec 2023 10:15:14 By NetDania Notify

Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year

11 Dec 2023 06:30:00 By Nasdaq GlobeNewswire

Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes

10 Dec 2023 18:30:00 By Nasdaq GlobeNewswire

Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes

10 Dec 2023 11:30:00 By Nasdaq GlobeNewswire

Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma

07 Dec 2023 06:00:45 By Nasdaq GlobeNewswire

Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO

07 Dec 2023 01:30:59 By Nasdaq GlobeNewswire

Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio

30 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease

27 Nov 2023 00:30:00 By Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentation

15 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)

13 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH

03 Nov 2023 06:00:14 By Nasdaq GlobeNewswire

Regeneron Reports Third Quarter 2023 Financial and Operating Results

02 Nov 2023 05:30:00 By Nasdaq GlobeNewswire

EYLEA® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema

01 Nov 2023 15:00:00 By Nasdaq GlobeNewswire

Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

26 Oct 2023 15:00:07 By Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

25 Oct 2023 15:05:00 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)

22 Oct 2023 13:59:00 By Nasdaq GlobeNewswire

Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)

21 Oct 2023 07:48:15 By Nasdaq GlobeNewswire